CALGARY, AB and MANTIN-VU, California, May 31, 2022 / PRNewswire / – Willow Biosciences Inc. (“Willow“or”The company“(TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on a revolution in the industrial production of clean, consistent and sustainable ingredients, is pleased to announce today that it is engaged in a specialty pharmaceutical company.”Counterparty“) to optimize an enzyme vital to the development of a large volume of Active Pharmaceutical Ingredient (API) used in nutraceuticals and pharmaceuticals. The contractor is collaborating with a multinational medical company with a large capitalization.

“This is a significant step forward in the evolution of the Willow business,” he said Trevor Peters, president and CEO of Willow. “This new partnership highlights the capabilities of our research team and demonstrates to our stakeholders the wide range of opportunities available for the integrated FutureGrown WillowTM technology platform. As Willow continues to expand its capabilities and add new partnerships, Willow is on track to become a leading name in bio-based production. ”

The project consists of stages of research, development and commercialization, revenues are derived from both research fees and payments for the stages. Following commercialization, Willow expects a steady stream of revenue from royalties.

About Willow Biosciences Inc.

Willow develops and manufactures high purity ingredients for personal care products, food and beverage and pharmaceutical markets. Willow’s future has grownTM The biotechnology platform allows large-scale production with sustainability at its core. Willow’s research and development team has proven experience in developing and commercializing production processes and biology-based products to benefit our B2B partners and their customers.

For more information, visit our website on www.willowbio.com

Statements about the future

This news release may include statements about the future, including opinions, assumptions, evaluations, and evaluations of the company’s future plans and operations, and in particular, statements regarding: a partner pharmaceutical project; demand and market potential of the synthetic cannabinoid industry; and the company’s business plan as a whole, including becoming a leader in precision fermentation, research and cannabinoid production. When used in this news release, the words “will”, “anticipate”, “believe”, “evaluate”, “expect”, “intention”, “perhaps”, “project”, “should” and similar expressions are intended to be among the statements which determine forward-looking statements. Statements about the future are based on expectations and assumptions made by the Company, which include, but are not limited to: the success of the Willow Strategic Partnership, including the development of future strategic partnerships; financial stability of the company; the company’s ability to fund its business plan using cash and existing resources; Willow product market; the company’s ability to obtain and maintain relevant licenses; the company’s ability to acquire suitable production partners and other strategic relationships; and the successful implementation of Willow’s commercialization and production strategy, in general. Statements about the future are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations presented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be met. Any number of important factors can cause actual results to differ materially from those contained in forward-looking statements, including, but not limited to, the risks associated with: the cannabinoid industry as a whole; the success of the company’s research and development strategy; infringement of intellectual property; inability to benefit from partnership or successful integration of acquisitions; actions and initiatives of federal and provincial governments and changes in government policy, as well as the implementation and impact of these actions, initiatives and policies; import / export restrictions and research for cannabinoid-based operations; the size of the market for cannabinoids for medical use and for adults; competition from other industry players; unfavorable economic conditions in the United States, Canada and the global economy; adverse global developments and crises in health care, including the current outbreak of COVID-19; non-compliance with certain rules; the departure of key management personnel or the inability to attract and retain talent; and other factors that are more fully described from time to time in reports and documents prepared by the Company to securities regulators. Please refer to the company’s latest annual information form and discussion and analysis guide for additional risk factors related to Willow, which are available on the Willow website at www.willowbio.com or under company profile on www.sedar.com.

Any financial perspective and future-oriented financial information contained in this document regarding future financial performance, financial position, cash or income balances based on assumptions about future events, including economic conditions and proposed courses of action based on management’s assessment of relevant information. which is currently available. The projected operational information contains forward-looking information and is based on a number of significant assumptions and factors, as outlined above. These projections can also be viewed as forward-looking financial information or financial projections. The actual results of the Company’s operations for any period are likely to differ from the amounts set out in these projections, and such changes may be material. Actual results will differ from those projected. Readers warn that any such financial prospects and forward-looking financial information contained in this document should not be used for purposes other than those for which it is disclosed herein.

Statements of the future contained in this news release are made as of the date of this notice, and the Company undertakes no obligation to publicly update or revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained in this document are clearly qualified in this warning statement.

See original content for multimedia downloads:https://www.prnewswire.com/news-releases/willow-biosciences-expands-its-portfolio-with-a-new-partnered-pharmaceutical-project-301557628.html

SOURCE Willow Biosciences Inc.

Source link